Pharmaceutical Technology

MARCH 30, 2023

Biogen/Eisai’s newly approved drug, Leqembi (lecanemab), gained FDA approval in January 2023 for the treatment of Alzheimer’s disease. The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is currently pending approval in the EU and Japan.

Sales 59

Sales FDA Marketing Competition 59

Pharmaceutical Technology

MARCH 30, 2023

Biogen/Eisai’s newly approved drug, Leqembi (lecanemab), gained FDA approval in January 2023 for the treatment of Alzheimer’s disease. The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is currently pending approval in the EU and Japan.

Sales 52

Sales FDA Marketing Competition 52

MedReps

SEPTEMBER 19, 2022

There’s no shortage of challenges for those new to pharma, medical sales and even veterans. Often we’re lucky if we even get to see our physicians, let alone overcome their objections regarding insurance coverage and competitive claims. Below are seven common challenges that pharmaceutical and other medical sales reps face.

Medical sales 66

Medical sales Medical sales reps Medical Sales 66

MedReps

JANUARY 30, 2023

Knowing what’s to come in the medical sales industry is not only interesting, but it could help you with your sales goals. If you know how to prepare and get ahead of your competition, reaching your goals will be that much easier. What does this mean for the medical sales representatives?

Medical sales 74

Medical sales Medical Sales Sales goal 74

pharmaphorum

DECEMBER 13, 2022

Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati’s adagrasib as Krazati for a form of lung cancer. Mirati also says its drug penetrates the central nervous system more readily, making it a better option for patients whose disease has metastasised to the brain.

FDA 52

FDA Side effects Competition Patients 52

MaBiCo

NOVEMBER 15, 2023

The Future of the Medical Sales Profession: Challenges and Approaches in a Fast-Changing Healthcare Market. Medical sales representatives are professionals who promote medical and health related products or services to healthcare providers, such as hospitals, clinics, pharmacies, and doctors.

Medical sales 52

Medical sales Medical sales reps Sales Medical 52

World of DTC Marketing

JULY 21, 2021

The FDA needs to study what people do when they see a DTC ad. Here are some myths around DTC marketing: 1ne: DTC ads result in patients asking for prescriptions they don’t need. Drug pricing is done by internal teams who look at what the market will bear and the competitive landscape. Again this is not true.

Marketing 285

Marketing Prescription Side effects Doctors 285

World of DTC Marketing

MAY 3, 2022

In trying to save the product, Biogen’s reputation was trashed by FDA advisors, HCPs, and the healthcare media. 2wo: The competition’s MS drugs were better – The MS market is lucrative, and competitors launched products that were better than Biogen’s with fewer side effects discussed by the MS community online.

Side effects 207

Side effects FDA Media Pharma 207

Evolve Your Success

OCTOBER 3, 2023

Diagnostic testing sales: where meticulous detail meets the human touch, changing the course of cancer care one relationship at a time. In this special episode for Breast Cancer Awareness Month, Veronica Vasek uncovers the challenges, triumphs, and the vital role that diagnostic sales reps play in the healthcare landscape.

Sales 64

Sales Medical sales Physicians Medical 64

Evolve Your Success

OCTOBER 24, 2023

OEM Sales is about creating solutions to win customers and making an impact, one deal at a time. In this episode, we have Sean Pitts from GCX corporation to uncover the ins and outs of OEM Sales. Sean discusses the critical qualities that make an exceptional OEM sales representative. If y ou ask, “W hat is OEM sales ?”

Sales 64

Sales Medical Manufacturing Medical sales 64

pharmaphorum

OCTOBER 17, 2022

The FDA is planning to take an additional three months to review Biogen’s experimental therapy for amyotrophic lateral sclerosis (ALS), setting back its decision date from January to April. There are around 31,000 patients with ALS in the US. The post FDA delays decision on Biogen’s ALS hope tofersen appeared first on.

FDA 52

FDA Prospecting Competition Safety 52

Pharmaceutical Technology

JUNE 7, 2023

Mounjaro’s approval for obesity, particularly in the US and EU markets, means the drug is entering a significantly large market where it will have direct competition from Novo Nordisk’s Wegovy (semaglutide), which is currently the leading glucagon-like peptide-1 (GLP-1) therapy approved for obesity by both the FDA and EMA.

Leads 98

Leads Marketing FDA Sales 98

Evolve Your Success

OCTOBER 31, 2023

Neuromodulation isn’t just about stimulating nerves; it’s about awakening hope and transforming lives—one patient at a time. In this episode, Blake Williams takes us on a wild journey through his career as a Field Clinical Engineer (FCE), shedding light on the incredible impact of neuromodulation on the lives of patients.

Engineering 52

Engineering Sales Medical sales Physicians 52

Evolve Your Success

JANUARY 31, 2023

In this episode, Samuel Adeyinka interviews John Crowder who covers how to sell effectively in medical sales. Tune in now and get medical sales-ready! — Watch the episode here Listen to the podcast here Selling Effectively In Medical Sales With John Crowder We have with us another special guest. I’m wonderful.

Medical sales 64

Medical sales Sales Medical Training 64

pharmaphorum

JANUARY 16, 2023

China’s Luye Pharma has claimed its first FDA approval, getting a green light for Rykindo, an injectable formulation of the antipsychotic risperidone given every two weeks. Analysts at GlobalData said last year that they expect LY03010 to launch in 2024 and bring in sales of around $64 million in 2030.

FDA 52

FDA Pharma Marketing Competition 52

pharmaphorum

SEPTEMBER 22, 2022

An analysis of 12-month data from the phase 3 VALOR trial of tofersen in patients with a rare form of ALS caused by a faulty SOD1 gene, plus as an open-label extension (OLE) study, has been published in the New England Journal of Medicine, showing the drug was effective in slowing progression of the disease.

FDA 52

FDA Sales Prospecting Patients 52

Evolve Your Success

JANUARY 23, 2024

In the changing balance between innovation and tradition, medical sales succeeds with personal connection, persistence, and the commitment to link technology and patient care. For today’s episode, we have Edouard Saget to discuss the big question: Will AI replace medical sales workforce and surgeons? Tune in to find out!

Medical sales 52

Medical sales Medical Sales Physicians 52

Pharmaceutical Technology

MARCH 24, 2023

Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. Amgen’s (US) Amjevita (adalimumab) is the first Humira biosimilar, launched in February 2023, and seven other FDA-approved biosimilars are expected to arrive on the US market later this year.

Competition 59

Competition Marketing FDA Physicians 59

Evolve Your Success

APRIL 11, 2023

Building your brand in medical device sales requires experience, strategic insights, and a relentless pursuit of excellence. With 40 years of medical device sales experience, Pat discusses how to build a successful medical device sales business. He also touches on the sales funnel, the art of hiring, and more.

Sales 52

Sales Medical Medical sales Media 52

PM360

APRIL 25, 2023

biosimilars market to date, the first of eight FDA-approved Humira (adalimumab) biosimilars launched in the United States in January after years of regulatory delays. Although AbbVie’s patent for Humira officially expired in 2016, the legal and regulatory delays paused competition for Humira until 2023. pharmaceutical industry.

Marketing 97

Marketing Competition Government Manufacturing 97

pharmaphorum

JANUARY 29, 2023

On Friday, Novartis said that the phase 3 STAND trial of Adakveo (crizanlizumab) found no statistically significant difference between the drug and placebo on annualised rates of vaso-occlusive crises (VOCs) – the excruciatingly painful attacks that intermittently affect patients with SCD. compared to 2.98 compared to 2.98

Competition 52

Competition Medicine FDA Marketing 52

Evolve Your Success

DECEMBER 6, 2022

Being a specialist in the medical sales field is no small feat because you have to really hone in on the nuances of that particular niche. That is what Shirley Taylor has done in the as a mammography sales specialist, focusing on breast imaging sales. Breast Imaging Sales With Shirley Taylor Part 1. That’s my niche.

Sales 52

Sales Medical sales Medical Management 52

Infuse Medical

SEPTEMBER 17, 2020

It’s no secret that being a medical sales rep is a difficult, but rewarding, profession. Sales reps are usually at the forefront of this pressure and have to work hard to make sure the product’s value is understood while adhering to the FDA regulations. Pick Your Medical Device Sales Tech Wisely. Web Conferencing Tool.

Pharmaceutical Sales 52

Pharmaceutical Sales Medical Sales Pharmaceutical 52

pharmaphorum

NOVEMBER 10, 2022

Clovis Oncology has said it may not have enough cash to fund continuing operations beyond January next year, as it struggles to reverse a decline in sales of PARP inhibitor Rubraca. Sales were around $140 million in 2019, and climbed to $165 million the following year, despite the impact of the pandemic.

Competition 57

Competition Sales Leads Marketing 57

pharmaphorum

AUGUST 31, 2022

The FDA will carry out a speedy review of Sanofi and Sobi’s once-weekly haemophilia A treatment efanesoctocog alfa (BIVV001), with a decision now expected by 28 February next year. The drug was one of the primary drivers for Sanofi’s $11.6 billion in the first half of this year.

Competition 52

Competition Marketing Sales Patients 52

pharmaphorum

OCTOBER 10, 2022

The results of the STELLAR trial showed that the activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein achieved a significant increase in exercise capacity measured using the six-minute walking test in PAH patients when added to stable background therapy, hitting its primary objectives.

Sales 52

Sales FDA Pharma Competition 52

pharmaphorum

JANUARY 19, 2023

per share deal includes $8 per share upfront, worth around $576 million, with the remainder in the form of a contingent value right (CVR) that will be paid to Concert shareholders if deuroxilitinib meets certain sales targets within a set time limit. The $11.50

Pharma 77

Pharma Marketing FDA Competition 77

pharmaphorum

NOVEMBER 24, 2022

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA’s decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC). Response rates above 50% in PD-1 high/intermediate patients with no liver tox surprises could set up for a potential acquisition.”

Pharma 98

Pharma Biopharma FDA Competition 98

European Pharmaceutical Review

JANUARY 10, 2023

Treatments identified in the report are predicted to be potential blockbuster drugs by 2027 or have potential to serve unmet patient needs for millions of patients worldwide. They have accounted for over 25 percent of Food and Drug Administration (FDA) approvals for the last seven years, the report found.

Food and Drug Administration 81

Food and Drug Administration FDA Food Medicine 81

European Pharmaceutical Review

NOVEMBER 8, 2022

There are also several pending bills that seek to lower drug costs by means other than price regulations, including: 1) deterring the delay in FDA approval of drug applications caused by sham ‘Citizen Petitions’. Citizen Petitions before the FDA. 562 would permit the FDA to deny the petition if either of these factors were satisfied.

Food and Drug Administration 52

Food and Drug Administration Pharma Prescription Manufacturing 52

Pharmaceutical Technology

APRIL 24, 2023

There, the data shows that patients on this regimen live longer lives along with having a greater period of time before disease progression, than with other treatments. CLL is regarded as the most common type of leukaemia in England where 3,157 patients were diagnosed with the disease in 2017, based on the institute’s announcement.

Food and Drug Administration 52

Food and Drug Administration Side effects Sales Food 52

pharmaphorum

JULY 28, 2022

Opdualag – a fixed-dose combination of LAG-3 inhibitor relatlimab and BMS’ PD-1 inhibitor Opdivo (nivolumab) – was approved as a first-line therapy for unresectable or metastatic melanoma by the FDA in March, and garnered $58 million in sales in the second quarter.

Sales 62

Sales Marketing Competition Manufacturing 62

pharmaphorum

SEPTEMBER 11, 2022

The US FDA has cleared the first-in-class tyrosine kinase 2 (Tyk2) inhibitor as Sotyktu , and BMS says it now plans to launch the new drug later this month, aiming to mount a challenge to Amgen’s $2.3 billion oral psoriasis therapy Otezla (apremilast). It had been approved since 2014 for moderate to severe cases only.

FDA 52

FDA Marketing Sales Patients 52

pharmaphorum

NOVEMBER 15, 2022

UK-based pharma Indivior has agreed a takeover deal with Opiant Pharma that consolidates its position in the addiction treatment category with a new intranasal therapy, due to be filed with the FDA before the end of the year. Opiant developed Narcan (naloxone nasal spray) as well. The deal is subject to regulatory approvals in the US and UK.

Sales 52

Sales FDA Pharma Marketing 52

pharmaphorum

DECEMBER 19, 2022

AbbVie has secured its fourth FDA approval for Vraylar, adding adjunctive therapy of major depressive disorder (MDD) to a list that includes schizophrenia and manic and depressive episodes in bipolar disorder. The FDA’s decision comes despite mixed results in clinical trials of the drug as an adjunctive treatment for depression.

FDA 52

FDA Marketing Competition Sales 52

pharmaphorum

JULY 18, 2022

. “The acceptance of the filing of proposed biosimilar natalizumab by the European regulatory authorities means we are a critical step closer to getting this important medicine to the patients who need it the most,” said Polpharma Biologics’ chief executive Michael Soldan in a statement.

Competition 52

Competition Marketing Sales Medicine 52

pharmaphorum

OCTOBER 13, 2022

Top-line results from phase ALPINE pitted the two drugs against each other in patients with previously treated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), and showed that Brukinsa (zanubrutinib) achieved better progression-free survival (PFS) compared to Imbruvica (ibrutinib), which made $10 billion in sales last year.

Side effects 52

Side effects Sales Marketing Competition 52